+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence

Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence

Autoimmunity Reviews 16(4): 352-354

To evaluate the clinical outcome after aPL (antiphospholipid antibodies) disappearance in primary APS patients. From a cohort of 70 patients with primary APS, we selected patients with positive aPL determinations at onset and ≥2 subsequent negative aPL determinations during the last 5years. To corroborate the immunologic profile, we determined IgG/IgM aCL antibodies, IgG/IgM antiβ2GPl, anti-annexin A5 antibodies and lupus anticoagulant (LA). All patients continued treatment with oral anticoagulants. Clinical data and aPL determinations at onset/after disappearance were obtained. descriptive statistics and Kaplan-Meier analysis. We found 24 patients with persistently negative aPL, including the last immunologic profile, 17 females, 7 males, mean age 51.7, disease evolution 16.3years, mean of 4 aPL previous positive determinations. aCL was positive at onset in 87.5%, 29% had double aPL positivity at onset (aCL/LA). Deep venous thrombosis (DVT) and ischemic stroke in 33% and pulmonary embolism in 12.5% were the most frequent manifestations at onset. INR range: 2-3. Time with aPL positive 109.4±80.7months. After 60months of follow-up since aPL disappearance, 45.8% of patients presented thrombosis recurrence, DVT in 9 patients, ischemic stroke in 1, pulmonary artery hypertension in 1. Other non-thrombotic APS manifestations were chronic ulcers in lower extremities and severe thrombocytopenia. This study suggest, that in primary APS, persistent negative aPL profile is not an indication to interrupt oral anticoagulant therapy. However, there is a subset of patients that remained asymptomatic. Other studies are necessary in order to elucidate this controversy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 059380923

Download citation: RISBibTeXText

PMID: 28216071

DOI: 10.1016/j.autrev.2017.02.004

Related references

Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome. La Revue de Medecine Interne 32(12): 724-729, 2011

Antiphospholipid-mediated thrombosis: interplay between type of antibodies and localisation of lung, and cardiovascular incidences in primary antiphospholipid syndrome. Clinical and Experimental Rheumatology 33(4): 531-536, 2015

Transient disappearance of serum antiphospholipid antibodies during the course of a thrombotic event in two adolescents with antiphospholipid syndrome receiving prednisone. Clinical and Experimental Rheumatology 12(4): 460-461, 1994

Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS/PT antibodies in primary antiphospholipid syndrome. Thrombosis Research 174: 141-147, 2019

Association of antiphospholipid antibodies and lupus anticoagulant with thrombosis in antiphospholipid syndrome. Lupus 10(Suppl. 1): S67, 2001

IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. Journal of Thrombosis and Haemostasis 14(8): 1530-1548, 2016

Antiphospholipid antibodies and antiphospholipid syndrome: role in portal vein thrombosis in patients with and without liver cirrhosis. Clinical and Applied Thrombosis/Hemostasis 17(4): 367-370, 2011

Activation of endothelial cells by antiphospholipid antibodies--a possible mechanism triggering thrombosis in patients with antiphospholipid syndrome. Kaohsiung Journal of Medical Sciences 22(10): 484-490, 2006

Antiphospholipid antibodies--antiphospholipid syndrome. Cause or consequence of thrombosis. Pathologie-Biologie 39(7): 709-715, 1991

Antiphospholipid syndrome--specificity of antiphospholipid antibodies and thrombosis. Nihon Rinsho Men'eki Gakkai Kaishi 22(1): 1-12, 1999

Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. Journal of Rheumatology 36(6): 1195-1199, 2009

Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis and Rheumatology 67(11): 2990-3003, 2015

THU0343Recurrent Thrombosis in Young Patients with Primary Antiphospholipid Syndrome: The Relevance of The Antiphospholipid Antibody Profile. Annals of the Rheumatic Diseases 75(Suppl 2): 311.1-311, 2016

THU0039 Relationship between Antiphosphatidylserine/Prothrombin Antibodies and Conventional Antiphospholipid Antibodies in Primary Antiphospholipid Syndrome. Annals of the Rheumatic Diseases 73(Suppl 2): 190-190, 2014

The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome. Clinical Rheumatology 35(5): 1361-1365, 2016